LPTX Leap Therapeutics, Inc.

7.85
0  -1%
Previous Close 7.90
Open 7.81
Price To book 0.00
Market Cap 73.74M
Shares 9,392,000
Volume 4,282
Short Ratio 0.46
Av. Daily Volume 28,128

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 enrollment complete. Update expected at ASCO 2017 - date TBC.
DKN-01
Cholangiocarcinoma
Phase 1/2 enrolling as of January 2017.
DKN-01
Esophageal cancer
Phase 3 data fail October 2015
CureXcell
Diabetic Foot Ulcers
Phase 3 endpoint not expected to be met - August 19, 2015.
CureXcell
Venous Leg Ulcers